Hep E vax provides 4 years of protection; Zimbabwe to launch HIV jab trial;

> Novavax ($NVAX) has appointed Brian Rosen as its VP of government affairs. Release

> Targovax is expanding expand an ongoing Phase I/II study of its cancer vaccine candidate. Release

> Scientists in Zimbabwe are preparing to launch the country's first-ever HIV vaccine trial. More

> A vaccine against hepatitis E provided protection against the virus for more than 4 years, researchers say. Report

And Finally... H7N9 bird flu has the makings of a pandemic virus, scientists caution. More

Read more on